Non-ST-elevation acute coronary

Palmer, S., M. Sculpher, M. Robinson Philips, L. Ginnelly, and D. Gary. 2005. Management of Non-ST-Elevation Acute Coronary Syndromes How Cost-Effective Are Glycoprotein Ilb/IIIa Antagonists in the UK National Health Service International Journal of Cardiology 100(2) 229-240. [Pg.310]

Boersma E, Akkerhuis KM, Theroux P et al, Platelet glycoprotein llb/llla receptor inhibition in non-ST-elevation acute coronary syndromes early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999 100 2045-2048. [Pg.56]

Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention an expert consensus. Am Heart J 2002 144 615-624. [Pg.84]

Alexander JH, Yang H, Becker RC, et al. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes results of the XaNADU-ACS Trial, J Thromb Haemost 2005 3 439 -47,... [Pg.126]

Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Circulation 2002 105 1760-1763. [Pg.472]

Heidenreich PA, Alloggiamento T> Melsop K, McDonald KM, Go AS, Hlatky MA. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes a meta analysis. J Am Coll Cardiol 2001 38 478-85. [Pg.1664]

Birnbaum Y, Atar S. Electrocardiogram risk stratification of non ST elevation acute coronary syndrome. J Electrocardiol 2006 39 558. [Pg.311]

Gomez-Hospital JA, Cequier A. The reality of invasive strategies in non-ST-elevation acute coronary syndrome. Rev Esp Cardiol 2004 57 1133. [Pg.315]

Nikus KC, Eskola MJ, Virtanen VK. ST-depression with negative T waves in leads V4-V5 - a marker of severe coronary artery disease in non-ST elevation acute coronary syndrome a prospective study of angina at rest, with troponin, clinical, electrocardiographic and angiographic correlation. Ann Noninvasive Electrocardiol 2004 9 207. [Pg.319]

FIGURE 2.2 Algorithm for patients with non-ST-elevation acute coronary syndrome managed by an early invasive strategy. (ACS, acute coronary syndrome UFH, unfractionated heparin PCI, percutaneous coronary intervention.)... [Pg.24]

Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomized trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome a follow-up study. Lancet 2006 368(9540) 998-1004. [Pg.42]

Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome the British Heart Foundation RITA 3 randomised trial. Lancet 2005 366(9489) 914-20. [Pg.42]

Cohen M, Hoekstra J, Giugliano R, et al. Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention an evidence-based review of clinical trial results and treatment guidelines report on a roundtable discussion. J Interv Cardiol 2008 21 283-99. [Pg.60]

Lincoff AM, Steinhubl SR, Manoukian SV, et al. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention. An analysis of the ACUITY Trial. JACC Cardiovasc Interv 2008 l(6) 639-48. [Pg.60]

Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Circulation 2002 105(15)4760-3. Ikonomidis I, Lekakis J, Revela I, et al. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J 2005 26(16)4618-24. [Pg.80]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...